. Istituto-nazionale-tumori, ". G. Fondazione, . Health, M. Bethesda, U. Boston et al., Franz Cancer Center, Providence Portland Medical Center 12 Department of Molecular Microbiology and Immunology, Oregon Health and Science University 14 INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris F-75006, France. 15 Université Paris Descartes 17 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai 19 Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute The Netherlands. 26 Peter MacCallum Cancer Centre, East Melbourne, Australia. 27 Unit of Cancer Genetics 38 Cancer Diagnosis Program, Center for Cancer Research, National Cancer Institute 3 Plastic and Reconstructive Surgery. 23 Humanitas Clinical and Research Institute. 29 Tumor Immunology Program, Jonsson Comprehensive Cancer Center (JCCC). 32 Global Early Clinical Development Institute of Applied Molecular Medicine (IMMA) Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology (CHI) Sidra Medical and Research Centre, pp.35-28668, 2013.

R. 1. Clark, W. Jr, L. From, E. Bernardino, and M. Mihm, The histogenesis and biologic behavior of primary human malignant melanomas of the skin, Cancer Res, vol.29, pp.705-727, 1969.

E. Korn, P. Liu, S. Lee, J. Chapman, D. Niedzwiecki et al., Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials, Journal of Clinical Oncology, vol.26, issue.4, pp.527-534, 2008.
DOI : 10.1200/JCO.2007.12.7837

K. Flaherty, I. Puzanov, K. Kim, A. Ribas, G. Mcarthur et al., Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-819, 2010.
DOI : 10.1056/NEJMoa1002011

G. Falchook, G. Long, R. Kurzrock, K. Kim, T. Arkenau et al., Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial, The Lancet, vol.379, issue.9829, pp.1893-1901, 2012.
DOI : 10.1016/S0140-6736(12)60398-5

. Van-den-eynde and . Bj, T cell defined tumor antigens, Current Opinion in Immunology, vol.9, issue.5, pp.684-693, 1997.
DOI : 10.1016/S0952-7915(97)80050-7

C. Gérard, N. Baudson, T. Ory, R. Piccininno, and V. Brichard, 118 POSTER Comprehensive preclinical model evaluating a protein-based MAGE-A3 specific cancer immunotherapy to fight against MAGE-A3 expressing tumors, European Journal of Cancer Supplements, vol.4, issue.12
DOI : 10.1016/S1359-6349(06)70124-0

W. Kruit, S. Suciu, B. Dreno, V. Chiarion-sileni, L. Mortier et al., Immunization with the recombinant MAGE-A3 protein combined with Adjuvant Systems AS02B or AS15 in patients with metastatic melanoma: final results of a Phase II study of the EORTC Melanoma Group, pp.0-0001, 2009.

J. Louahed, F. Lehmann, F. Ulloa-montoya, O. Gruselle, B. Dizier et al., Abstract A37: Identification of a gene expression signature predictive of clinical activity following MAGE-A3 ASCI treatment, Molecular Cancer Therapeutics, vol.8, issue.Supplement 1, p.1, 2009.
DOI : 10.1158/1535-7163.TARG-09-A37

J. Yuan, M. Adamow, B. Ginsberg, T. Rasalan, E. Ritter et al., Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab, Proceedings of the National Academy of Sciences, vol.108, issue.40, pp.16723-16728, 2011.
DOI : 10.1073/pnas.1110814108

O. Donnell-tormey, J. Mcdermott, and E. Jr, The cancer vaccine collaborative: a new model of coordinated discovery, Cancer Immun, vol.12, p.10, 2012.

K. Wheatley, N. Ives, A. Eggermont, J. Kirkwood, N. Cascinelli et al., on behalf of International Malignant Melanoma Collaborative Group: Interferon-? as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials [abstract], Proc Am Soc Clin Oncol, vol.25, pp.478-8526, 2007.

S. Mocellin, S. Pasquali, C. Rossi, and D. Nitti, Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis, JNCI Journal of the National Cancer Institute, vol.102, issue.7, pp.493-501, 2010.
DOI : 10.1093/jnci/djq009

S. Moschos, H. Edington, S. Land, U. Rao, D. Jukic et al., Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses, Journal of Clinical Oncology, vol.24, issue.19, pp.3164-3171, 2006.
DOI : 10.1200/JCO.2005.05.2498

W. Wang, H. Edington, U. Rao, D. Jukic, S. Land et al., Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFN??2b, Clinical Cancer Research, vol.13, issue.5, pp.1523-1531, 2007.
DOI : 10.1158/1078-0432.CCR-06-1387

Z. Yurkovetsky, J. Kirkwood, H. Edington, A. Marrangoni, L. Velikokhatnaya et al., Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-??2b, Clinical Cancer Research, vol.13, issue.8, pp.2422-2428, 2007.
DOI : 10.1158/1078-0432.CCR-06-1805

S. Meyer, P. Wild, T. Vogt, F. Bataille, C. Ehret et al., Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma, Experimental Dermatology, vol.18, issue.8, pp.251-257, 2010.
DOI : 10.1111/j.1600-0625.2010.01072.x

E. Wang, Y. Zhao, A. Monaco, L. Uccellini, J. Kirkwood et al., A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon, PLoS ONE, vol.7, issue.7, p.40805, 2012.
DOI : 10.1371/journal.pone.0040805.s001

H. Gogas, J. Kirkwood, C. Falk, U. Dafni, V. Sondak et al., Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon, Cancer, vol.13, issue.18, pp.4326-4333, 2010.
DOI : 10.1002/cncr.25211

H. Gogas, U. Dafni, H. Koon, M. Spyropoulou-vlachou, Y. Metaxas et al., Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial, Journal of Translational Medicine, vol.8, issue.1, p.108, 2010.
DOI : 10.1186/1479-5876-8-108

W. Wang, D. Yu, A. Sarnaik, Y. B. Hall, M. Morelli et al., Biomarkers on melanoma patient T Cells associated with ipilimumab treatment, Journal of Translational Medicine, vol.10, issue.1, p.146, 2012.
DOI : 10.1002/eji.200939261

J. Irish, R. Hovland, P. Krutzik, O. Perez, Ø. Bruserud et al., Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells, Cell, vol.118, issue.2, pp.217-228, 2004.
DOI : 10.1016/j.cell.2004.06.028

A. Cesano, D. Rosen, O. Meara, P. Putta, S. Gayko et al., Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: Effect of specimen source (bone marrow or peripheral blood) on assay readouts, Cytometry Part B: Clinical Cytometry, vol.116, issue.3, pp.158-172, 2012.
DOI : 10.1002/cyto.b.21007

T. Covey and A. Cesano, Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications, Best Practice & Research Clinical Haematology, vol.23, issue.3, pp.319-331, 2010.
DOI : 10.1016/j.beha.2010.07.002

T. Covey, A. Cesano, and D. Parkinson, Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease, Autoimmunity, vol.114, issue.1, pp.550-559, 2010.
DOI : 10.1038/nmeth872

D. Longo, B. Louie, S. Putta, E. Evensen, J. Ptacek et al., Single-Cell Network Profiling of Peripheral Blood Mononuclear Cells from Healthy Donors Reveals Age- and Race-Associated Differences in Immune Signaling Pathway Activation, The Journal of Immunology, vol.188, issue.4, pp.1717-1725, 2012.
DOI : 10.4049/jimmunol.1102514

D. Hotson, A. Conroy, E. Evensen, G. Gentilcore, E. Simeone et al., CTLA-4 defines distinct T cell signaling populations in healthy donors and metastatic melanoma patients [abstract], J Immunother, vol.2012, p.35760

M. Kashani-sabet, S. Venna, M. Nosrati, J. Rangel, A. Sucker et al., A Multimarker Prognostic Assay for Primary Cutaneous Melanoma, Clinical Cancer Research, vol.15, issue.22, pp.6987-6992, 2009.
DOI : 10.1158/1078-0432.CCR-09-1777

D. Semir, D. Nosrati, M. Bezrookove, V. Dar, A. Federman et al., Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis, Proceedings of the National Academy of Sciences, vol.109, issue.18, pp.7067-7072, 2012.
DOI : 10.1073/pnas.1119949109

J. Kirkwood, J. Ibrahim, J. Sosman, V. Sondak, S. Agarwala et al., High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801, Journal of Clinical Oncology, vol.19, issue.9, pp.2370-2380, 2001.
DOI : 10.1200/JCO.2001.19.9.2370

A. Eggermont, S. Suciu, M. Santinami, W. Kruit, A. Testori et al., EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-??2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.29, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.8506b

H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-giokas, K. Frangia et al., Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon, New England Journal of Medicine, vol.354, issue.7, pp.709-718, 2006.
DOI : 10.1056/NEJMoa053007

P. Ascierto and J. Kirkwood, Adjuvant therapy of melanoma with interferon: lessons of the past decade, Journal of Translational Medicine, vol.6, issue.1, p.62, 2008.
DOI : 10.1186/1479-5876-6-62

K. Kumar, J. Liu, Y. Li, D. Yu, A. Thomas-tikhonenko et al., Raf inhibitor stabilizes receptor for the type I interferon but inhibits its antiproliferative effects in human malignantmelanoma cells, Cancer Biol Ther, vol.6, pp.1437-1441, 2007.

A. Tarhini, J. Cherian, S. Moschos, H. Tawbi, Y. Shuai et al., Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma, Journal of Clinical Oncology, vol.30, issue.3, pp.322-328, 2012.
DOI : 10.1200/JCO.2011.37.5394

W. Peng, C. Liu, C. Xu, Y. Lou, J. Chen et al., PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-?? Inducible Chemokines, Cancer Research, vol.72, issue.20, pp.5209-5218, 2012.
DOI : 10.1158/0008-5472.CAN-12-1187

D. Lawson, S. Lee, A. Tahrini, K. Margolin, M. Ernstoff et al., E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma., Journal of Clinical Oncology, vol.28, issue.15_suppl, p.288507, 2010.
DOI : 10.1200/jco.2010.28.15_suppl.8504

L. Flaherty, J. Moon, M. Atkins, R. Tuthill, J. Thompson et al., Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG [abstract], J Clin Oncol, vol.30, p.8504, 2012.

W. Overwijk, A. Tsung, K. Irvine, M. Parkhurst, T. Goletz et al., gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of ???Self???-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand, The Journal of Experimental Medicine, vol.157, issue.2, pp.277-286, 1998.
DOI : 10.1016/1074-7613(95)90170-1

E. Hodis, I. Watson, G. Kryukov, S. Arold, M. Imielinski et al., A Landscape of Driver Mutations in Melanoma, Cell, vol.150, issue.2, pp.251-263
DOI : 10.1016/j.cell.2012.06.024

M. Davies and Y. Samuels, Analysis of the genome to personalize therapy for melanoma, Oncogene, vol.157, issue.41, pp.5545-5555, 2010.
DOI : 10.1038/onc.2008.244

D. Dankort, D. Curley, R. Cartlidge, B. Nelson, A. Karnezis et al., BrafV600E cooperates with Pten loss to induce metastatic melanoma, Nature Genetics, vol.17, issue.5, pp.544-552, 2009.
DOI : 10.1038/75973

S. Rosenberg, J. Yang, R. Sherry, U. Kammula, M. Hughes et al., Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy, Clinical Cancer Research, vol.17, issue.13, pp.4550-4557, 2011.
DOI : 10.1158/1078-0432.CCR-11-0116

A. Boni, A. Cogdill, P. Dang, D. Udayakumar, C. Njauw et al., Selective BRAF V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function, Cancer Res, issue.13, pp.705213-5219, 2010.

R. Cartlidge, G. Thomas, S. Cagnol, K. Jong, S. Molton et al., Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival, Pigment Cell & Melanoma Research, vol.9, issue.5, pp.534-544, 2008.
DOI : 10.1111/j.1755-148X.2008.00491.x
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916913

K. Boisvert-adamo and A. Aplin, Mutant B-RAF mediates resistance to anoikis via Bad and Bim, Oncogene, vol.5, issue.23, pp.3301-3312, 2008.
DOI : 10.1016/S0092-8674(00)81382-3

H. Sumimoto, F. Imabayashi, T. Iwata, and Y. Kawakami, The BRAF???MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells, The Journal of Experimental Medicine, vol.63, issue.7, pp.1651-1656, 2006.
DOI : 10.1002/ijc.21286

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011.
DOI : 10.1056/NEJMoa1103782

S. Kopetz, J. Desai, E. Chan, J. Hecht, O. Dwyer et al., PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract], J Clin Oncol, p.28, 2010.

A. Prahallad, C. Sun, S. Huang, D. Nicolantonio, F. Salazar et al., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature, vol.15, issue.7388, pp.100-104, 2012.
DOI : 10.1038/nature10868

K. Kim, M. Cabanillas, A. Lazar, M. Williams, D. Sanders et al., Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring V600EBRAF Mutation. Thyroid 2013. [Epub ahead of print] PubMed PMID: 23489023, p.137

H. Yang, B. Higgins, K. Kolinsky, K. Packman, Z. Go et al., RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models, Cancer Research, vol.70, issue.13, pp.72045518-5527, 2010.
DOI : 10.1158/0008-5472.CAN-10-0646

R. Sullivan, D. Lawrence, K. Flaherty, D. Mcdermott, J. Aldridge et al., Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay [abstract], J Clin Oncol, vol.2012, p.30

A. Hauschild, J. Grob, L. Demidov, T. Jouary, R. Gutzmer et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, pp.358-365, 2012.
DOI : 10.1016/S0140-6736(12)60868-X

R. Gonzalez, A. Ribas, A. Daud, A. Pavlick, T. Gajewski et al., Phase Ib study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7) [abstract], Ann Oncol, vol.23, p.20, 2012.

H. Tiano, C. Loftin, J. Akunda, C. Lee, J. Spalding et al., Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis, Cancer Res, vol.62, pp.3395-3401, 2002.

K. Trunzer, A. Pavlick, L. Schuchter, R. Gonzalez, G. Mcarthur et al., Ribas A: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma, J Clin Oncol, 2013.

R. Nazarian, H. Shi, Q. Wang, X. Kong, R. Koya et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.66, issue.7326, pp.973-977, 2010.
DOI : 10.1038/nature09626

S. Whittaker, J. Theurillat, E. Van-allen, N. Wagle, J. Hsiao et al., A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition, Cancer Discovery, vol.3, issue.3, pp.350-362, 2013.
DOI : 10.1158/2159-8290.CD-12-0470

O. Maertens, B. Johnson, P. Hollstein, D. Frederick, Z. Cooper et al., in Melanomagenesis, Cancer Discovery, vol.3, issue.3, pp.338-349, 2013.
DOI : 10.1158/2159-8290.CD-12-0313

E. Chiocca, Oncolytic viruses, Nature Reviews Cancer, vol.2, issue.12, pp.938-950, 2002.
DOI : 10.1038/nrc948

C. Kudo-saito, J. Schlom, and J. Hodge, Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses, Clinical Cancer Research, vol.11, issue.6, pp.2416-2426, 2005.
DOI : 10.1158/1078-0432.CCR-04-1380

N. Senzer, H. Kaufman, T. Amatruda, M. Nemunaitis, T. Reid et al., Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor???Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma, Journal of Clinical Oncology, vol.27, issue.34, pp.5763-5771, 2009.
DOI : 10.1200/JCO.2009.24.3675

G. Trinchieri, L06.03 * GUT COMMENSAL BACTERIA DETERMINE CANCER RESPONSE TO TREATMENT BY MODULATING SYSTEMIC INFLAMMATION, Annals of Oncology, vol.24, issue.suppl 1, p.12, 2013.
DOI : 10.1093/annonc/mdt042.26

G. Trinchieri, Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts, Annual Review of Immunology, vol.30, issue.1, pp.677-706, 2012.
DOI : 10.1146/annurev-immunol-020711-075008

. Cataissonc, . Salcedor, . Hakims, . Moffittba, . Wrightl et al., TrinchieriG:IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis, pp.1689-1702, 2012.

A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, Cancer-related inflammation, Nature, vol.342, issue.7203, pp.436-444, 2008.
DOI : 10.1038/nature07205

A. Sica and A. Mantovani, Macrophage plasticity and polarization: in vivo veritas, Journal of Clinical Investigation, vol.122, issue.3, pp.787-795, 2012.
DOI : 10.1172/JCI59643DS1

A. Mantovani, P. Romero, A. Palucka, and F. Marincola, Tumour immunity: effector response to tumour and role of the microenvironment, The Lancet, vol.371, issue.9614, pp.771-783, 2008.
DOI : 10.1016/S0140-6736(08)60241-X

S. Biswas, P. Allavena, and A. Mantovani, Tumor-associated macrophages: functional diversity, clinical significance and open questions. Semin Immunopathology 2013

B. Bottazzi, A. Doni, C. Garlanda, and A. Mantovani, An Integrated View of Humoral Innate Immunity: Pentraxins as a Paradigm, Annual Review of Immunology, vol.28, issue.1, pp.157-183, 2010.
DOI : 10.1146/annurev-immunol-030409-101305

G. Beatty, E. Chiorean, M. Fishman, B. Saboury, U. Teitelbaum et al., CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans, Science, vol.331, issue.6024, pp.401612-1616, 2011.
DOI : 10.1126/science.1198443

G. Germano, R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce et al., Role of Macrophage Targeting in the Antitumor Activity of Trabectedin, Cancer Cell, vol.23, issue.2, pp.249-262, 2013.
DOI : 10.1016/j.ccr.2013.01.008

C. Balch, J. Gershenwald, S. Soong, J. Thompson, M. Atkins et al., Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, pp.6199-6206, 2009.
DOI : 10.1200/JCO.2009.23.4799

A. Spatz, M. Cook, D. Elder, M. Piepkorn, D. Ruiter et al., Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas, European Journal of Cancer, vol.39, issue.13, pp.1861-1865, 2003.
DOI : 10.1016/S0959-8049(03)00325-3

V. Winnepenninckx, V. Lazar, S. Michiels, P. Dessen, M. Stas et al., Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome, JNCI Journal of the National Cancer Institute, vol.98, issue.7, pp.472-482, 2006.
DOI : 10.1093/jnci/djj103

B. Elliott, R. Scolyer, S. Suciu, S. Lebecque, D. Rimoldi et al., Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma, Clinical Cancer Research, vol.13, issue.13, pp.3825-3830, 2007.
DOI : 10.1158/1078-0432.CCR-07-0358

A. Eggermont, S. Suciu, R. Mackie, W. Ruka, A. Testori et al., Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial, The Lancet, vol.366, issue.9492, pp.1189-1196, 2005.
DOI : 10.1016/S0140-6736(05)67482-X

A. Eggermont, S. Suciu, M. Santinami, A. Testori, W. Kruit et al., Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial, The Lancet, vol.372, issue.9633, pp.117-126, 2008.
DOI : 10.1016/S0140-6736(08)61033-8
URL : https://hal.archives-ouvertes.fr/hal-00485095

A. Eggermont, S. Suciu, A. Testori, W. Kruit, J. Marsden et al., Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991, European Journal of Cancer, vol.48, issue.2, pp.218-225, 2012.
DOI : 10.1016/j.ejca.2011.09.028

A. Eggermont, S. Suciu, A. Testori, M. Santinami, W. Kruit et al., Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma, Journal of Clinical Oncology, vol.30, issue.31, pp.303810-3818, 2012.
DOI : 10.1200/JCO.2011.41.3799

K. Mcmasters, M. Edwards, M. Ross, D. Reintgen, R. Martin et al., Ulceration as a Predictive Marker for Response to Adjuvant Interferon Therapy in Melanoma, Transactions of the ... Meeting of the American Surgical Association, vol.128, pp.460-465, 2010.
DOI : 10.1097/SLA.0b013e3181f20bb1

R. Gerlingerm, . Horswells, J. Larkin, D. Endesfelder, E. Gronroos et al., C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, pp.883-892, 2012.

A. Seghers, S. Wilgenhof, C. Lebbé, and B. Neyns, Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor, Melanoma Research, vol.22, issue.6, pp.466-472, 2012.
DOI : 10.1097/CMR.0b013e3283541541

E. Koay and E. Sulman, Management of Brain Metastasis: Past Lessons, Modern Management, and Future Considerations, Current Oncology Reports, vol.21, issue.2, pp.70-78, 2012.
DOI : 10.1007/s11912-011-0205-9

N. Rochet, L. Kottschade, and S. Markovic, Vemurafenib for Melanoma Metastases to the Brain, New England Journal of Medicine, vol.365, issue.25, pp.2439-2441, 2011.
DOI : 10.1056/NEJMc1111672

B. Engelhardt and R. Ransohoff, The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms, Trends in Immunology, vol.26, issue.9, pp.485-495, 2005.
DOI : 10.1016/j.it.2005.07.004

M. Davies, K. Stemke-hale, E. Lin, C. Tellez, W. Deng et al., Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma, Clinical Cancer Research, vol.15, issue.24, pp.7538-7546, 2009.
DOI : 10.1158/1078-0432.CCR-09-1985

N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci et al., Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel, Clinical Cancer Research, vol.12, issue.4, pp.1317-1324, 2006.
DOI : 10.1158/1078-0432.CCR-05-1634

E. Hersh, D. Vecchio, M. Brown, M. Kefford, R. Loquai et al., Phase 3, randomized, open-label, multicenter trial of nabpaclitaxel (nab-P) versus dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM) [abstract], Pigment Cell Melanoma Res, vol.25, p.863, 2012.

L. Gattinoni, E. Lugli, Y. Ji, Z. Pos, C. Paulos et al., A human memory T cell subset with stem cell???like properties, Nature Medicine, vol.79, issue.10, pp.1290-1297, 2011.
DOI : 10.1084/jem.20051357

L. Uccellini, D. Giorgi, V. Zhao, Y. Tumaini, B. Erdenebileg et al., gene polymorphisms in melanoma, J Transl Med, vol.10, p.5170, 2012.

T. Wendler, K. Herrmann, A. Schnelzer, T. Lasser, J. Traub et al., First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT, European Journal of Nuclear Medicine and Molecular Imaging, vol.14, issue.Pt 2, pp.1452-1461, 2010.
DOI : 10.1007/s00259-010-1430-4

G. Gerlini, C. Urso, G. Mariotti, D. Gennaro, P. Palli et al., Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes, Clinical Immunology, vol.125, issue.2, pp.184-193, 2007.
DOI : 10.1016/j.clim.2007.07.018

G. Gerlini, D. Gennaro, P. Mariotti, G. Urso, C. Chiarugi et al., Human Langerhans cells are immature in melanoma sentinel lymph nodes, Blood, vol.119, issue.20, pp.4807-4808, 2012.
DOI : 10.1182/blood-2011-12-401067

G. Gerlini, S. Sestini, D. Gennaro, P. Urso, C. Pimpinelli et al., Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy, Clinical & Experimental Metastasis, vol.66, issue.1, pp.37-45, 2013.
DOI : 10.1007/s10585-012-9505-1

G. Gerlini, D. Gennaro, P. Borgognoni, and L. , Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation, OncoImmunology, vol.4, issue.9, pp.1655-1657, 2012.
DOI : 10.1056/NEJMoa1112824

J. Pingpank, S. Libutti, R. Chang, B. Wood, Z. Neeman et al., Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies, Journal of Clinical Oncology, vol.23, issue.15, pp.3465-3474, 2005.
DOI : 10.1200/JCO.2005.00.927

J. Pingpank, M. Hughes, M. Faries, J. Zager, H. Alexander et al., A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma., Journal of Clinical Oncology, vol.28, issue.18_suppl
DOI : 10.1200/jco.2010.28.18_suppl.lba8512

B. Seliger, Novel insights into the molecular mechanisms of HLA class I abnormalities, Cancer Immunology, Immunotherapy, vol.285, issue.40, pp.249-254, 2012.
DOI : 10.1007/s00262-011-1153-9

L. Amiot, S. Ferrone, H. Grosse-wilde, and B. Seliger, Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?, Cellular and Molecular Life Sciences, vol.103, issue.3, pp.417-431, 2011.
DOI : 10.1007/s00018-010-0583-4
URL : https://hal.archives-ouvertes.fr/hal-00682022

J. Nemunaitis, D. Sterman, D. Jablons, J. Smith, B. Fox et al., Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer, JNCI Journal of the National Cancer Institute, vol.96, issue.4, pp.326-331, 2004.
DOI : 10.1093/jnci/djh028

C. Twitty, S. Jensen, H. Hu, and B. Fox, Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism, Clinical Cancer Research, vol.17, issue.20, pp.6467-6481, 2011.
DOI : 10.1158/1078-0432.CCR-11-0812

G. Kenter, M. Welters, A. Valentijn, M. Lowik, D. Der-meer et al., Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia, New England Journal of Medicine, vol.361, issue.19, pp.1838-1847, 2009.
DOI : 10.1056/NEJMoa0810097

M. Welters, G. Kenter, P. Devosvansteenwijk, M. Löwik, D. Berends-van-der-meer et al., Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses, Proceedings of the National Academy of Sciences, vol.107, issue.26, pp.11895-11899, 2010.
DOI : 10.1073/pnas.1006500107

L. Calabrò, R. Danielli, L. Sigalotti, and M. Maio, Clinical Studies With Anti???CTLA-4 Antibodies in Non-melanoma Indications, Seminars in Oncology, vol.37, issue.5, pp.460-467, 2010.
DOI : 10.1053/j.seminoncol.2010.09.006

F. Vidal-vanaclocha, L. Mendoza, N. Telleria, C. Salado, M. Valcárcel et al., Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression, Cancer and Metastasis Reviews, vol.103, issue.Suppl 1, pp.417-434, 2006.
DOI : 10.1007/s10555-006-9013-3

F. Vidal-vanaclocha, G. Fantuzzi, L. Mendoza, A. Fuentes, M. Anasagasti et al., IL-18 regulates IL-1beta -dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1, Proceedings of the National Academy of Sciences, vol.97, issue.2, pp.734-739, 2000.
DOI : 10.1073/pnas.97.2.734

O. Crende, M. Sabatino, M. Valcárcel, T. Carrascal, P. Riestra et al., Metastatic lesions with interleukin-18 dependent and independent genes in advanced stage melanoma patients, Am J Pathol, 2013.

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006.
DOI : 10.1126/science.1129139

W. Fridman, F. Pages, C. Sautes-fridman, and J. Galon, The immune contexture in human tumours: impact on clinical outcome, Nature Reviews Cancer, vol.29, issue.4, pp.298-306, 2012.
DOI : 10.1038/nrc3245

B. Mlecnik, M. Tosolini, P. Charoentong, A. Kirilovsky, G. Bindea et al., Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer, Gastroenterology, vol.138, issue.4, pp.1429-1440, 2010.
DOI : 10.1053/j.gastro.2009.10.057

F. Pagès, A. Kirilovsky, B. Mlecnik, M. Asslaber, M. Tosolini et al., In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5944-5951, 2009.
DOI : 10.1200/JCO.2008.19.6147

B. Mlecnik, M. Tosolini, A. Kirilovsky, A. Berger, G. Bindea et al., Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction, Journal of Clinical Oncology, vol.29, issue.6, pp.610-618, 2011.
DOI : 10.1200/JCO.2010.30.5425

J. Galon, F. Pagès, F. Marincola, M. Thurin, G. Trinchieri et al., The immune score as a new possible approach for the classification of cancer, Journal of Translational Medicine, vol.10, issue.1, 2012.
DOI : 10.1186/1479-5876-9-32
URL : https://hal.archives-ouvertes.fr/inserm-00664981

J. Galon, F. Pagès, F. Marincola, H. Angell, M. Thurin et al., Cancer classification using the Immunoscore: a worldwide task force, Journal of Translational Medicine, vol.10, issue.1, p.205, 2012.
DOI : 10.1186/1479-5876-10-1
URL : https://hal.archives-ouvertes.fr/inserm-00780742

. Ascierto, Future perspectives in melanoma research. Meeting report from the ???Melanoma Bridge. Napoli, December 2nd-4th 2012???, Journal of Translational Medicine, vol.11, issue.1, p.137, 2012.
DOI : 10.1186/1479-5876-10-205
URL : https://hal.archives-ouvertes.fr/inserm-00834025